TWM
SPRY icon

Tripletail Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Tripletail Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$1.17K – 270
2025
Q4 		$1.17K Sell
100
-350
-78% -$3.4K ﹤0.01% 261
2025
Q3 		$4.66K Buy
+450
New +$6.46K 0.01% 287

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Tripletail Wealth Management's SPRY Position: Q1 2026 in Review

Tripletail Wealth Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 100 shares — an estimated $1.17K sold.

Tripletail Wealth Management first reported a position in SPRY in Q3 2025 and held it in 2 quarters. The position peaked at $4.66K in Q3 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Tripletail Wealth Management reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tripletail Wealth Management sold 100 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.17K.
  • Tripletail Wealth Management first reported a position in ARS Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Tripletail Wealth Management's ARS Pharmaceuticals position peaked at $4.66K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Tripletail Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.